These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28283692)

  • 1. Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis.
    Dymond AW; Elks C; Martin P; Carlile DJ; Mariani G; Lovick S; Huang Y; Lorch U; Brown H; So K
    Eur J Clin Pharmacol; 2017 Jun; 73(6):717-726. PubMed ID: 28283692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
    Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
    J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
    Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
    Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
    Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
    Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
    Dymond AW; Martin P; So K; Huang Y; Severin P; Holmes V; Mariani G; Marbury T
    J Clin Pharmacol; 2017 May; 57(5):592-605. PubMed ID: 28019010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
    Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
    J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of telmisartan in Chinese patients with mild to moderate essential hypertension
.
    Pei Q; Yang L; Tan HY; Liu SK; Liu Y; Huang L; Li RH; Wan Q; Huang J; Guo CX; Zuo XC; Li J; Yang GP
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):659-665. PubMed ID: 28518053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Zalikowski J; Chen Y; Kim K; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):329-40. PubMed ID: 25630984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
    Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
    Tong X; Xu H; Carlile DJ; Tomkinson H; Al-Huniti N; Zhou D
    J Clin Pharmacol; 2019 Jan; 59(1):112-122. PubMed ID: 30102413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
    Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
    Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
    Hu P; Chen J; Liu D; Zheng X; Zhao Q; Jiang J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):843-50. PubMed ID: 25995169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
    Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
    Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
    Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
    PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers.
    Toda R; Shiramoto M; Komai E; Yoshii K; Hirayama M; Kawabata Y
    J Clin Pharmacol; 2018 Apr; 58(4):425-433. PubMed ID: 29193126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
    Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
    Lu S; Nand RA; Yang JS; Chen G; Gross AS
    Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.